Home

Partnering Compounds

Compound Principal Target Stage of Development

XL228

IGF1R, SRC
Phase 1
 

XL413

Cdc7
Phase 1
 

XL888

HSP90
Phase 1
 

XL388

TORC 1 & 2
IND
 

XL541

S1P1R antagonist
Preclinical
 

XL499

PI3Kδ
Preclinical
 

FXR

FXR
Preclinical
 

S1P1R agonists

S1P1R agonists
Preclinical
  • About Exelixis
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Strategic Alliances
    • Locations
    • Contact Us
  • Cabozantinib
    • Clinical Trial Information
    • Bone Metastases
    • Preclinical Rationale and Results
    • Frequently Asked Questions
  • Pipeline
    • Cabozantinib (XL184)
    • Out-Licensed Compounds
    • Partnering Compounds
  • Investors
    • Management and Board
    • Corporate Governance
    • Stock Information
    • Analyst Coverage
    • Earnings Estimates
    • Earnings Ratings
    • Annual Reports
    • SEC Filings
    • Press Releases
    • Non-GAAP Financial Measures
    • Event Calendar
    • Information Request
    • Investor FAQs
    • Contact IR
  • Resources
    • Events
    • ASCO 2011 Online Summit
    • CEO Topic
    • Data Presentations
  • Careers
    • Job Opportunities
    • Benefits
    • Events
    • Awards
  • Contact Us

Pipeline

  • Cabozantinib (XL184)
  • Out-Licensed Compounds
  • Partnering Compounds
    • XL228
    • XL413
    • XL888
    • XL388
    • XL541
    • XL499
© Exelixis, Inc. 2012   Website design: Hane Chow, Inc.
  • Terms of Use